However, numerousstudies have indicated that resistance to dabrafenib monotherapy can develop viasecondary genetic alterations and expression, increasing MAPK signaling andcontinued cancer growth (36).Another observation of dabrafenib monotherapy was that a large number of patientswere diagnosed with secondary skin cancers, which were associated with contradictoryactivation of the MAPK pathway in nonmutant BRAF cells (37). Here, BRAF is linked to skin neoplasm.